Random Shit 2024 Flashcards

learn random shit

1
Q

What anti-angiogenic agent binds angiopoiten 1 and 2?

A

Trebaninib

(also AMG 386)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which has highest risk of EOC?
BRIP1
PALB2
RAD51C
RAD51D

A

RAD51D (10-20%) > RAD51C = BRIP1 (10-15%) >PALB2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is most radiosensitive in the bone marrow?
Erythrocytes
megalokarocytes
leukocytes
granulocytes

A

Leukocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Framework of the Doctor-Patient relationship

A

Paternalistic Model: vests majority of decision-making power in the doctor.

Informative Model: vests the majority of decision-making power in the patient. The doctor provides the patient with all relevant information so he/she can made a decision.

Interpretive Model: provides a greater role for the doctor to assist the patient in understanding her values and interests, and the possible impact of different interventions in these terms. The doctor acts as an advisor.

Deliberative Model: the doctor has a role in judging and prioritizing patient values. The doctor indicates both what the patient could do and, in the context of their understanding of the patient’s life and values, what he thinks the patient should do in terms of choice of intervention.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the Hayflick limit?

A

number of times cell divides based on shortening of telomeres

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

PARPS SPECIFIC SIDE EFFECTS

A

NIRAPARIB (Zejula): HTN, thrombocytopenia

OLAPARIB (Lynparza): Pneumonitis, transient Cr elevation, anemia or myelosupression

Rucaparib (Rubraca: Liver enzymes elevation, transient Cr elevation interaction w/MATE1/2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CHEK 2 Gene

A

CHEK2 encodes a cell cycle checkpoint kinase associated with the deoxyribonucleic acid (DNA) damage repair response Fanconi anemia (FA)-BRCA1/2 pathway (upstream of BRCA)
-dsDNA break –> ATM –> CHEK2 –>p53

Breast cancer lifetime risks for frameshift variants: 20 to 40%.

Also associated with 5-10% risk colon cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tisotumab Vedontin (Tivdak)

A

Antibody-drug conjugate used in recurrent or metastatic cervical cancer. Binds TF.

Tisotumab (a monoclonal antibody against tissue factor) + monomethyl auristatin E (binds to tubulin and microtubules causing microtubule dysregulation and suppressing microtubule dynamics).

Side Effect: Causes severe ocular toxicities (severe vision loss and corneal ulceration). Bleeding risk (epistaxis)

MOA:
1. Tivdak binds to TF-expressing cells
2. The Tivdak-TF complex is internalized and trafficked to the lysosomes
3. MMAE is released from the antibody via proteolytic cleavage
4. MMAE disrupts the microtubule network of actively dividing cells
5. This leads to cell cycle arrest and apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Insulin and Endometrial cancer

A

STIMULATE RAS/RAF/MAPK and PI3K/AKT Pathways.
DOWNREGULATE IGFBP.
STIMULATES IGF1 ACTIVITY.

MOA:
Insulin promotes cell proliferation and survival through ACTIVATION OR STIMULATION of the ras–raf –MAPK and PI3K–AKT pathways.

Indirectly, insulin leads to changes in sex hormones, including increased estrogen levels, with ensuing REDUCTION OR INHIBITION in IGFBP1 levels, a negative regulator of IGF1.

The net result of IGFBP1 downregulation is a major INCREASE in IGF1 activity.

2004 study: women with endometrial cancer had lower levels of insulin-like growth factor binding protein-3 (IGFBP-3) than controls.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

EGFR Inhibitors

A

Tyrosine Kinase Small Molecule Inhibitors: Erlotinib and Gefitinib . Bind to tyrosine kinase domain via competitive blockade of ATP binding, blocking EGFR enzymatic activity.

Monoclonal antibodies: Cetuximab and Panitumumab. Bind to the extracellular domain of EGFR and prevent ligand dependent signaling, blocking cell growth and survival signals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

TILS in ovarian cancer

A

High grade serous OC (HGSOC) has been shown to be more frequently infiltrated with TILs.

Increased levels of CD8+ TILs is positively correlated with OS, not only in HGSOC but also in endometrioid carcinoma.

Increased levels of Treg is associated with a higher death hazard ratio and aggressive type of cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Characteristics of BRCA related breast cancers

A

BRCA1 tumors: basal-like cancer subtype by gene expression profiling. ER-, PR-, Her2- and are mutant for p53. Mostly invasive ductal carcinoma with medullary features.

BRCA2 tumors: more commonly express ER hormone receptors with approximately 35% being classified as the luminal A subtype (hormone +, her2 neg), and 40% being classified as luminal B (hormone +, her2 +/-, more aggressive).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Mechanisms of resistance to PARP inhibitors

A
  1. Restoration of Homologous Recombinations capacity (the most common acquired PARPis resistance mechanism*)
  2. BRCA reversion mutations restoring protein function
  3. Stabilization of replication forks
  4. Increased drug efflux
  5. Inhibition of PARP trapping and glycohydrolase
  6. Alteration in cell cycle control (cyclin-dependent kinase 12 and WEE1 are cell-cycle regulators involved in PARPis resistance due to their ability to restore HR)
  7. Dysregulated signal pathways: upregulation of the PI3K/AKT pathway, upregulation of the ATM/ATR pathway,
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Most common type of neoplastic colon polyp

A

Tubular Adenoma
About 70 percent of all polyps are adenomatous (tubular adenoma), making it the most common type of colon polyp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What cells are CD56 positive?

A

NK cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Stat Tests:
Paired- parametric, nonparametric
Unpaired-parametric, nonparametric

A

Paired tests:
Comparing 2 things:
-paired T test (parametric)=Wilcoxon rank (non-para)
Comparing 3+ things:
-ANOVA (parametric) = Friedman (non-para)

Unpaired/Independent:
Comparing 2 things:
-unpaired T/students T (para)=Mann-Whitney U (non-para)
Comparing 3+ things:
-ANOVA (para) = Kruskal-Wallis

ANOVA= analysis of variance

17
Q

Cancers with:
BRCA1
BRCA2

A

BRCA1: Breast, ovary, male breast, prostate, pancreatic, uterine serous
BRCA2: Breast, ovary, male breast, prostate, pancreatic, melanoma, stomach, GB, bile duct, salivary

18
Q

STIC Management

A

Per NCCN:
1) observation alone with or without CA-125 testing when no evidence of invasive cancer is noted
2) surgical staging with observation or chemotherapy based on NCCN Guidelines if invasive cancer is noted.

For those without prior genetic counseling and/or testing, discovery of a STIC should prompt a genetics evaluation.

It is not clear whether surgical staging and/or adjuvant chemotherapy is beneficial for those with STIC

19
Q

Immune Escape Mechanisms

A
  1. Downregulate MHC
  2. Tumor Ag loss
  3. Stimulate inhibitory receptors on T cells (CTLA-4, PD1, LAG3) this was answer option
  4. overproduce indoleamine 2,3 deoxygenase
  5. increase tumor infiltration by Tregs and NKT cells to limit immune destruction
20
Q

Warfarin reversal options

A

Vit K (takes time)

Immediate=FFP and prothrombin complex concentrate

21
Q

Shock types and associated changes

A
22
Q

Emetogenic Drugs

A

Highly Emetic > 90%: Cisplatin, Cyclophosphamide, Anthracyclines

Minimally Emetic < 10%:
Bev
Bleo
Nivo/Pembro
Trastuzumab
Vincas

23
Q

Leukemogenic Chemos

A

Melphalan (10%), Etoposide (1%), Cisplatin, Cyclophosphamide (<1%)

5-FU low leukemogenic potential

24
Q

Lynch Syndrome cancer risks by mutation

A

MLH1 - 30-50% risk EC (4-20% Ovary)(46-60% colorectal, highest)
PMS2 - 13-25% risk EC (1-3% ovary) (8-20% colorectal, lowest for all)
MSH2 - 20-50% risk EC (8-38% ovary, highest) (33-52% colorectal)
MSH6 - 16-50% risk EC (1-13% ovary)(10-40% colorectal)

25
Q

K and Ca EKG Changes

A
26
Q

Dopamine Doses and Effects

A

LOW DOSE (0.5 to <2 mcg/kg/min):
- Mainly activates DOPAMINE-1
receptors in the renal, mesenteric, cerebral and coronary beds resulting in selective vasodilation and increasing blood flow.

INTERM DOSE (5 to 10 mcg/kg/min):
- stimulates BETA-1 adrenergic receptors and increases CO, by increasing SV with variable effects on heart rate.

HIGH DOSE (> 10 mcg/kg/min):
- Stimulate alpha-adrenergic receptors and produce vasoconstriction with an increased SVR.

27
Q

Imatinib (Gleevec) MOA

A
  • Small molecule inhibitor targeting multiple tyrosine kinases such as:
    CSF1R, ABL, c-KIT (through RAS/RAF/MEK pathway) and PDGFR-β
  • Specifically used to treat CML and ALL that are Philadelphia chromosome positive t(9;22)(q34;q11).
  • Also treats (GIST) > KIT positive
  • Side effects: gastrointestinal symptoms, musculoskeletal and skin reactions, bone marrow suppression (neutropenia/thrombocytopenia), fluid retention
28
Q

Ethics Principles

A